Last $9.37 USD
Change Today +0.08 / 0.86%
Volume 61.0K
GNMK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 12:37 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

genmark diagnostics inc (GNMK) Snapshot

Open
$9.38
Previous Close
$9.29
Day High
$9.43
Day Low
$9.27
52 Week High
05/9/13 - $16.00
52 Week Low
08/8/13 - $8.75
Market Cap
392.7M
Average Volume 10 Days
311.4K
EPS TTM
$-0.92
Shares Outstanding
41.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMARK DIAGNOSTICS INC (GNMK)

Related News

No related news articles were found.

genmark diagnostics inc (GNMK) Related Businessweek News

No Related Businessweek News Found

genmark diagnostics inc (GNMK) Details

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual’s ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual’s increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company’s diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company is engaged in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.

153 Employees
Last Reported Date: 03/11/14

genmark diagnostics inc (GNMK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $443.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $183.1K
Senior Vice President of Global Operations & ...
Total Annual Compensation: $236.9K
Senior Vice President of Sales
Total Annual Compensation: $203.9K
Compensation as of Fiscal Year 2012.

genmark diagnostics inc (GNMK) Key Developments

GenMark Diagnostics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:40 AM

GenMark Diagnostics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:40 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

GenMark Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Announces Impairment of Intangible Asset for the Fourth Quarter Ended December 31, 2013

GenMark Diagnostics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company's revenues were $6.5 million compared with $9.4 million during the fourth quarter of 2012. The 32% decrease in total fourth quarter revenue was attributable to a decrease in purchases from Natural Molecular Testing Corporation (NMTC) during the current period, which was offset by significant growth in both reagent and instrument revenue from other customers. Loss per share was $0.26 compared with $0.15 in the fourth quarter of 2012. On a non-GAAP basis, loss per share was $0.21 compared to $0.15 per share a year ago. On a non-GAAP basis, net loss was $8.567 million compared to $4.695 million a year ago. Net loss was $10.632 million against $4.693 million a year ago. Loss from operations was $10.271 million against $4.595 million of prior year. Loss before income taxes was $10.618 million against $4.588 million of prior year. For the year, the company reported revenue was $27.4 million, compared to $20.5 million for the prior year, an increase of 34%. Net loss was $33.6 million or a $0.95 loss per share compared to net loss of $22.1 million or $0.84 loss per share for the prior year. On a non-GAAP basis, loss per share was $0.82 compared to $0.84 per share a year ago. On a non-GAAP basis, net loss was $28.755 million compared to $22.103 million a year ago. Loss from operations was $34.880 million against $21.891 million of prior year. Loss before income taxes was $33.599 million against $21.955 million of prior year. Net cash used in operating activities was $23.796 million against $16.243 million of prior year. Purchases of property and equipment were $4.270 million against $3.476 million of prior year. For the fourth quarter ended December 31, 2013, the company recorded impairment of intangible asset of $1,624,000.

GenMark Diagnostics, Inc. to Report Q4, 2013 Results on Mar 11, 2014

GenMark Diagnostics, Inc. announced that they will report Q4, 2013 results at 5:00 PM, Eastern Standard Time on Mar 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNMK:US $9.37 USD +0.08

GNMK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid Inc $47.81 USD +1.67
Luminex Corp $17.07 USD +0.32
Nanosphere Inc $1.87 USD 0.00
QIAGEN NV €14.84 EUR +0.63
Sequenom Inc $2.57 USD +0.07
View Industry Companies
 

Industry Analysis

GNMK

Industry Average

Valuation GNMK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.9x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMARK DIAGNOSTICS INC, please visit www.genmarkdx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.